Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Use of propranolol in treating hemangiomas

Yasaman R. Shayan, Julie S. Prendiville and Ran D. Goldman
Canadian Family Physician March 2011; 57 (3) 302-303;
Yasaman R. Shayan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie S. Prendiville
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran D. Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Question I see many children with infantile hemangiomas and have read about new therapeutic options such as propranolol. Is this medication effective and safe for treating hemangiomas in children?

Answer Most infantile hemangiomas resolve spontaneously without any need for therapy. In many case series, propranolol has been shown to be effective and safe in treating hemangiomas that cause complications. Further studies are required to determine the optimal dose and duration of propranolol treatment for problematic hemangiomas.

Infantile hemangiomas are the most common vascular tumours in children, occurring in 5% to 10% of infants.1 Although most are small cutaneous hemangiomas, they can also be large, disfiguring lesions with serious complications. Hemangiomas might also involve the orbit, airway, or visceral organs, such as the liver, brain, intestinal tract, or lungs.2 They generally become evident within the first days to months of life and are characterized by an initial phase of rapid endothelial cell proliferation during the first year of life and a phase of slow involution.3

Complications

Although most hemangiomas are benign and managed by “watchful waiting,” about 10% can cause complications requiring intervention or management by a multidisciplinary team.2 The most common complication is ulceration, which might result in bleeding, pain, infection, difficulty feeding, and residual scarring.4 Hemangiomas can cause airway obstruction and visual disturbance depending on their location. A rare complication of hepatic hemangiomas is hypothyroidism secondary to a high level of triiodothyronine deiodinase activity within these hemangiomas.2 Large hemangiomas can also be associated with high-output heart failure as a result of arteriovenous shunting within the hemangioma.2 Spinal cord dysraphism and other underlying structural anomalies are associated with segmental hemangiomas in the lumbosacral region. Similarly, extensive lesions on the head and neck can be associated with a spectrum of disease, including posterior fossa malformations, cerebrovascular anomalies, coarctation of the aorta, sternal dysraphism, ocular disease, and airway involvement.

Management

For most cases of infantile hemangiomas, only parental education and reassurance are required. Hemangiomas with the potential to threaten a child’s life or vital functions and those that ulcerate or cause substantial disfigurement warrant treatment. This might include medical or surgical therapy, or a combination of both. The approach to the treatment of a hemangioma should be individualized and based on its location, size, and severity of complications. Complicated hemangiomas are generally managed by pediatric dermatologists, vascular anomalies teams, or other specialists with experience in the field.

Until recently, systemic corticosteroids were the first-line medical therapy for most complicated hemangiomas. Their mechanism of action is poorly understood. The standard treatment regimen is 2 to 4 mg/kg of oral prednisone or prednisolone daily.2 A meta-analysis5 reviewed 24 case series of infants who were treated with systemic steroids. The patients received a mean dose of 2.9 mg/kg of prednisone daily for an average of 1.8 months. The response rate was found to be 84%, with the greatest response occurring in children treated in the early proliferative phase of the lesion. Intralesional and topical steroids were found to be useful in small and superficial hemangiomas only.6

Alternatives to systemic corticosteroid treatment of aggressive and steroid-unresponsive hemangiomas have included interferon-α and vincristine. Ezekowitz et al7 found a 90% response rate to interferon-α, an angiogenesis inhibitor, in 20 neonates who failed corticosteroid therapy. However, interferon is rarely used owing to concerns about its side effect profile. One meta-analysis8 showed that 11% of 441 patients treated with interferon developed permanent spastic diplegia. Vincristine inhibits microtubule growth, and in a small case report it was used with success in the treatment of corticosteroid-resistant hemangiomas.9 Its main side effects include constipation and peripheral neuropathy. It is generally administered via a central catheter under the supervision of an oncologist.

Nonpharmacologic treatments of hemangiomas include pulsed-dye laser therapy and excisional surgery. Laser therapy is of benefit only for superficial hemangiomas and might induce ulceration in the early proliferative stage. Surgical excision is effective for complicated localized hemangiomas, depending on the site of involvement, and for correction of cosmetically substantial residual skin changes. Embolization by an interventional radiologist might be considered for hemangiomas in which arteriovenous shunting is causing serious cardiac overload.9

Old medication, new use

Propranolol—a non-selective β-blocker developed in the 1950s by Sir James Black, who was awarded the 1988 Nobel Prize in Medicine—was the first β-adrenergic receptor antagonist found to be useful in clinical medicine.9

In 2008, a group of physicians from Bordeaux Children’s Hospital in France described an interesting observation from several patients with extensive infantile hemangiomas10 who received concomitant treatment with propranolol (for obstructive hypertrophic cardiomyopathy and high cardiac output). In each case, the hemangioma regressed upon initiation of propranolol and the children were eventually weaned from corticosteroids without recurrence of hemangioma growth.10 In the same article, the authors also described similar findings in 9 other children with substantially large hemangiomas whom they treated with propranolol. In a follow-up report, 32 children with complicated hemangiomas treated with propranolol experienced immediate colour changes and effects on growth in all cases,11 with only one patient discontinuing the drug owing to respiratory wheezing.

The mechanism of action of propranolol is unclear. It is hypothesized that as a β-adrenergic antagonist it induces vasoconstriction, resulting in colour change and palpable softening of the hemangioma, even within 24 hours of treatment,10 or that propranolol might cause down-regulation of growth factors, such as vascular endothelial growth factor, and up-regulation of cellular apoptosis.9,10

Propranolol is generally a safe drug, but it has been associated with adverse events such as bradycardia, hypotension, hypoglycemia, and bronchospasm.11,12 Lawley et al12 described a case in which a neonate taking propranolol had a critically low serum glucose level while being completely asymptomatic. They suggested that the β-blockade most likely caused the child to be asymptomatic and, for this reason, they recommended caution in the widespread use of propranolol.12 Some authors recommend that all patients should have electrocardiograms and echocardiograms before commencing propranolol therapy to rule out contraindications to β-blockade.11,12 Slow upward titration of the drug and close monitoring of heart rate, blood pressure, and serum glucose levels have also been recommended in the initial phase of treatment.11,12

Conclusion

Propranolol has recently been found to be efficacious in treating problematic infantile hemangiomas. All the research in this field has been observational thus far. Results of a randomized control trial are awaited to assess the safety, efficacy, and optimal dose and duration of propranolol treatment. Although it appears to be well tolerated in most infants, hypoglycemia is a well-documented adverse effect. The side effect profile of propranolol in this population of infants needs ongoing evaluation.

Notes

PRETx

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program (www.pretx.org) at the BC Children’s Hospital in Vancouver, BC. Drs Shayan and Prendiville are members and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875–2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Kilcline C,
    2. Frieden IJ
    . Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008;25(2):168-73.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kliegman RM,
    2. Behrman RE,
    3. Jenson HB,
    4. Stanton BF
    . Nelson textbook of pediatrics. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007. p. 3147.
  3. 3.↵
    1. Chang LC,
    2. Haggstrom AN,
    3. Drolet BA,
    4. Baselga E,
    5. Chamlin SL,
    6. Garzon MC,
    7. et al
    . Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008;122(2):360-7.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Chamlin SL,
    2. Haggstrom AN,
    3. Drolet BA,
    4. Baselga E,
    5. Frieden IJ,
    6. Garzon MC,
    7. et al
    . Multicenter prospective study of ulcerated hemangiomas. J Pediatr 2007;151(6):684-9, 689.e1. Epub 2007 Aug 24.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Bennett ML,
    2. Fleischer AB,
    3. Chamlin SL,
    4. Frieden IJ
    . Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001;137(9):1208-13.
    OpenUrlPubMed
  6. 6.↵
    1. Akhavan A,
    2. Zippin JH
    . Current treatments for infantile hemangiomas. J Drugs Dermatol 2010;9(2):176-80.
    OpenUrlPubMed
  7. 7.↵
    1. Ezekowitz RA,
    2. Mulliken JB,
    3. Folkman J
    . Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326(22):1456-63.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Michaud AP,
    2. Bauman NM,
    3. Burke DK,
    4. Manaligod JM,
    5. Smith RJ
    . Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004;114(7):1231.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Zimmermann AP,
    2. Wiegand S,
    3. Werner JA,
    4. Eivazi B
    . Propranolol therapy of infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol 2010;74(4):338-42. Epub 2010 Feb 1.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Léauté-Labrèze C,
    2. Dumas de la Roque E,
    3. Hubiche T,
    4. Boralevi F,
    5. Thambo JB,
    6. Taïeb A
    . Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358(24):2649-51.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Sans V,
    2. Dumas de la Roque E,
    3. Berge J,
    4. Grenier N,
    5. Boralevi F,
    6. Mazereeuw-Hautier J,
    7. et al
    . Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124(3):e423-31. Epub 2009 Aug 10.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Lawley LP,
    2. Siegfried E,
    3. Todd JL
    . Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009;26(5):610-4.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 57 (3)
Canadian Family Physician
Vol. 57, Issue 3
1 Mar 2011
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Use of propranolol in treating hemangiomas
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Use of propranolol in treating hemangiomas
Yasaman R. Shayan, Julie S. Prendiville, Ran D. Goldman
Canadian Family Physician Mar 2011, 57 (3) 302-303;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Use of propranolol in treating hemangiomas
Yasaman R. Shayan, Julie S. Prendiville, Ran D. Goldman
Canadian Family Physician Mar 2011, 57 (3) 302-303;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Complications
    • Management
    • Old medication, new use
    • Conclusion
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Activation of Hedgehog Signaling in Aggressive Hepatic Hemangioma in Newborns and Infants
  • Google Scholar

More in this TOC Section

Practice

  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
Show more Practice

Child Health Update

  • Accidental cannabis ingestion in young children
  • All-terrain vehicle injuries in children and adolescents
  • Screen time and sleep in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire